[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06143202":3,"trial-entities:NCT06143202":96,"trial-summary:NCT06143202":101},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":25,"primary_purpose":26,"phases":27,"enrollment_info":28,"interventions":31,"primary_outcomes":38,"secondary_outcomes":43,"sex":57,"minimum_age":58,"maximum_age":59,"healthy_volunteers":15,"eligibility_criteria":60,"std_ages":64,"locations":67,"central_contacts":92,"overall_officials":93,"references":94,"see_also_links":95},"NCT06143202","23-1051","Feasibility of CGM Use in Hospitalized Youth","Feasibility of Continuous Glucose Monitor Use In Hospitalized Youth","ENROLLING_BY_INVITATION","2027-02-14","2026-02","2026-03-03","2025-07-15","University of Colorado, Denver","OTHER",false,"This study is assessing the feasibility of a continuous glucose monitor during hospital admissions in youth and young adults with hyperglycemia due to diabetes or other underlying conditions that requires frequent glucose monitoring, through patient\u002Ffamily and nursing staff feedback on their perspectives and usability of the system in the hospital will be assessed through surveys. In addition, retrospective glycemic comparisons between CGM data and POC will be conducted.","Youth and young adult patients admitted to the hospital for any reason, but require glucose monitoring during the hospitalization will be enrolled in this study. Participant diagnosis can include type 1 diabetes, type 2 diabetes, medication-induced diabetes, cystic fibrosis-related diabetes, or other causes of hyperglycemia that it has been determined by the hospital team requires frequent glucose monitoring, with or without insulin management.\n\nEnrolled participants will wear a blinded continuous glucose monitor for up to 28 days (2 sensors) or until the end of their hospitalization. In addition, enrolled participants will complete a survey to assess their perspectives on the CGM wear experience and interest in future CGM use during hospitalizations. Nursing staff of the enrolled participant will also be invited to complete a survey regarding their perspectives of CGM use in the hospital setting.",[19],"Hyperglycemia",[19,21,22,23,24],"Continuous glucose monitors","Pediatrics","Hospital","Diabetes","OBSERVATIONAL",null,[],{"count":29,"type":30},120,"ESTIMATED",[32],{"type":33,"name":34,"description":35,"armGroupLabels":36},"DEVICE","Freestyle Libre 3 Continuous Glucose Monitor","Youth and young adult participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.",[37],"You and young adult patients with hyperglycemia",[39],{"measure":40,"description":41,"timeFrame":42},"Retrospective glycemic CGM and point of care comparison","Glycemic data related to time in range, time hypoglycemic, time hyperglycemic and the time of first onset of hypoglycemia and hyperglycemia will be obtained by both CGM and point of care glucose values.","Duration of study, approximately 1 year from study start",[44,48,51,54],{"measure":45,"description":46,"timeFrame":47},"Nursing staff perspectives of CGM use in the hospital","Surveys will be provided to the nursing staff associated with an enrolled patient participant to obtain qualitative perspectives on the usability of CGMs in the hospital setting","Duration of study, approximately to 1 year from study start",{"measure":49,"description":50,"timeFrame":42},"Patient\u002FFamily perspectives of CGM use in the hospital","Surveys will be completed by patients\u002Ffamily to evaluate their experience with sensor wear in the hospital, sensor insertion, and goals for glycemic monitoring while in the hospital.",{"measure":52,"description":53,"timeFrame":42},"Feasibility of CGM use through assessment of discontinuation and data loss","Identify the frequency and causes of sensor discontinuation as well as information on sensor data loss.",{"measure":55,"description":56,"timeFrame":42},"Health economics data","Pilot analysis of health economics data from costs related to glycemic monitoring during the hospitalization.","ALL","2 Years","26 Years",{"inclusion":61,"exclusion":62,"raw_text":63},[],[],"Inclusion Criteria:\n\n1. Participants will be 2 to less than 26 years of age at the time of enrollment.\n2. Participants will have a diagnosis of type 1 diabetes, type 2 diabetes, diabetes\u002Fhyperglycemia due to an underlying condition (such as in cystic fibrosis, monogenic diabetes), or medication induced diabetes\u002Fhyperglycemia (such as steroid-induced hyperglycemia or PEG-asparaginase induced hyperglycemia) and would benefit clinically from close glucose monitoring during hospitalization due to fluctuations in blood glucose values.\n3. Participant is expected to be in the hospital for longer than 12 hours after study enrollment with a goal of 36 hours or more as determined by study investigator or trained staff.\n4. Participant is willing to wear the continuous glucose monitor for the duration of the hospital admission or the lifespan of a continuous glucose monitor (7-14 days).\n\nExclusion Criteria:\n\n1. Has had a history of a significant skin reaction to the adhesives of a continuous glucose monitor in the past or concerns that one may occur due to underlying skin conditions (ie severe eczema, uncontrolled psoriasis, etc).\n2. Planned MRI or surgery during the study device use (can be enrolled pre or post procedure if sufficient time for sensor wear as determined by investigator \\[i.e. 24-48 before planned procedure\\]).\n3. Admission to inpatient psychiatry.\n4. Pregnancy.\n5. Currently using hydroxyurea.\n6. A condition that the investigator determines would prevent the patient from participation.",[65,66],"CHILD","ADULT",[68,77,84],{"facility":69,"city":70,"state":71,"zip":72,"country":73,"geoPoint":74},"University of California San Francisco","San Francisco","California","94158","United States",{"lat":75,"lon":76},37.77493,-122.41942,{"facility":78,"city":79,"state":71,"zip":80,"country":73,"geoPoint":81},"Stanford University","Stanford","94305",{"lat":82,"lon":83},37.42411,-122.16608,{"facility":85,"city":86,"state":87,"zip":88,"country":73,"geoPoint":89},"University of Colorado, Barbara Davis Center","Aurora","Colorado","80045",{"lat":90,"lon":91},39.72943,-104.83192,[],[],[],[],{"nct_id":4,"conditions":97,"biomarkers":100},[98,99,19],"Cystic Fibrosis","Diabetes Mellitus",[],{"nct_id":4,"found":15,"summary":26,"prompt_version":26}]